Tetraphase Pharmaceuticals Inc. (NASDAQ:TTPH) rose 5.2% during trading on Friday . The stock traded as high as $4.45 and last traded at $4.42, with a volume of 182,044 shares trading hands. The stock had previously closed at $4.20.

TTPH has been the subject of several research analyst reports. Zacks Investment Research upgraded shares of Tetraphase Pharmaceuticals from a “hold” rating to a “buy” rating and set a $4.75 price target for the company in a research report on Wednesday, July 6th. BMO Capital Markets assumed coverage on shares of Tetraphase Pharmaceuticals in a research note on Monday, April 11th. They issued a “market perform” rating and a $8.00 price objective on the stock. Needham & Company LLC reiterated a “hold” rating on shares of Tetraphase Pharmaceuticals in a research note on Saturday, May 14th. Wedbush reiterated a “neutral” rating and issued a $4.00 price objective on shares of Tetraphase Pharmaceuticals in a research note on Monday, June 20th. Finally, Gabelli reiterated a “neutral” rating on shares of Tetraphase Pharmaceuticals in a research note on Monday, May 16th. Twelve investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company. Tetraphase Pharmaceuticals has a consensus rating of “Hold” and a consensus price target of $20.80.

The stock’s market cap is $159.97 million. The stock’s 50-day moving average price is $4.19 and its 200-day moving average price is $4.87.

Tetraphase Pharmaceuticals (NASDAQ:TTPH) last announced its quarterly earnings data on Wednesday, May 4th. The biopharmaceutical company reported ($0.46) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.44) by $0.02. The firm had revenue of $2 million for the quarter, compared to analyst estimates of $2.20 million. During the same quarter in the previous year, the company posted ($0.66) earnings per share. The firm’s quarterly revenue was down 33.3% compared to the same quarter last year. Equities research analysts anticipate that Tetraphase Pharmaceuticals Inc. will post ($1.96) earnings per share for the current fiscal year.

An institutional investor recently raised its position in Tetraphase Pharmaceuticals stock. California Public Employees Retirement System raised its position in Tetraphase Pharmaceuticals Inc. (NASDAQ:TTPH) by 1,459.3% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 276,000 shares of the biopharmaceutical company’s stock after buying an additional 258,300 shares during the period. California Public Employees Retirement System owned about 0.76% of Tetraphase Pharmaceuticals worth $2,768,000 at the end of the most recent reporting period.

Tetraphase Pharmaceuticals, Inc (Tetraphase) is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. It is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.